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Along with other investigations, patients presenting to an environmental health clinic with various chronic conditions were
assessed for bone health status. Individuals with compromised bone strength were educated about skeletal health issues and
provided with therapeutic optionsforpotential ameliorationof their bonehealth. Patients who declined pharmacotherapyor who
previously experienced failure of drug treatment were oﬀered other options including supplemental micronutrients identiﬁed in
the medical literature as sometimes having a positive impact on bone mineral density (BMD). After 12 months of consecutive
supplemental micronutrient therapy with a combination that included vitamin D3, vitamin K2, strontium, magnesium and
docosahexaenoicacid(DHA),repeat bonedensitometrywasperformed. Theresultswere analyzedinagroupofcompliantpatients
and demonstrate improved BMD in patients classiﬁed with normal, osteopenic and osteoporotic bone density. According to the
results, this combined micronutrient supplementation regimen appears to be at least as eﬀective as bisphosphonates or strontium
ranelate in raising BMD levels in hip, spine, and femoral neck sites. No fractures occurred in the group taking the micronutrient
protocol. This micronutrient regimen also appears to show eﬃcacy in individuals where bisphosphonate therapy was previously
unsuccessful in maintainingor raising BMD. Prospective clinical trials are required to conﬁrm eﬃcacy.
1.Introduction
Disordered bone health is an age-related illness that aﬀects
an increasing proportion of the population in many western
nations. Throughout much of the developed world, the
fastest growing segment of the current population is the
baby-boomer generation, the group born during the post-
WWII baby boom that is rapidly approaching retirement.
Accordingto theStatisticsCanada 2006Census, forexample,
baby-boomers account for one-third of the country’s 32
million people, 20% of which are in the 55–64 age class and
soon toleavetheworkforce[1].Olderpatientswith lowbone
density are at high risk for falls and fragility fractures [2],
w h i c hi nt u r nc a u s ec o n s i d e r a b le morbidity and subsequent
mortality as well as exerting an enormous ﬁnancial burden
on public health care systems [3]. With an aging population,
preventionofage-relateddiseasesincludingosteoporosisand
related fragility fractures will continue to play an important
role in the sustainability and implementation of good per-
sonal and public health care.
Asimprovedbonemineral density(BMD)hasbeenasso-
ciated with a diminished risk of fragility fractures, preferred
BMD status in greater proportions of the population would
deliver not only improved quality of life but also signiﬁcant
cost savings. With escalating rates of osteoporosis in various
jurisdictions overthe last decade,it would be desirable if pri-
mary prevention strategies to obviate the development of
compromised bone health could be instituted as well as
nontoxic interventions to restore bone strength in those with
deﬁcient BMD.
Recent clinical practice guidelines for the diagnosis and
managementofimpaired bonehealthhaveprimarily focused
on pharmacologic therapy and lifestyle modiﬁcations to pre-
vent fragility fractures and their adverse sequelae [4–6].2 Journal of Environmental and Public Health
Pharmaceuticalinterventionstoaddressabnormalboneden-
sity have focused to a great degree on antiresorptive bispho-
sphonates. Other medications considered in select situations
may include other antiresorptive agents such as a human
monoclonal antibody RANK ligand inhibitor (Denosumab),
a bone forming analog to parathyroid hormone (Teripara-
tide), strontium ranelate, calcitonin, and hormonal replace-
ment therapy or a selective estrogen receptor modulator for
postmenopausal women [4, 7].
A recent study has shown, however, that lack of com-
pliance with current osteoporosis protocols is putting the
elderly at increased risk for fragility fractures and associated
morbidity and mortality [8]. Moreover, increasing numbers
of patients decline osteoporosis pharmacotherapy because
of media attention to potential adverse eﬀects and legal
proceedingsrelatedtooutcomesallegedtobeconnectedwith
some osteoporosis medications. For example, recent con-
cerns about long-term hormone replacement therapy [9, 10]
and media reports about atypical fractures [11], osteonecro-
sis [12], atrial ﬁbrillation [13], and esophageal cancer [14]
allegedly associated with bisphosphonate use has led some
patients to pursue other approaches to ameliorate bone
health despite the fact that the link between these medica-
tions and all the purported adverse side eﬀects still remains
controversial [13, 15].
Various micronutrients have recently been identiﬁed in
the scientiﬁc and biochemistry literature as integral to the
proper development, physiology, and maintenance of bone.
Depletion of essential nutrients for bone health because of
inadequate intake, impaired digestion, malabsorption, or
disordered assimilation may result in deﬁcient biochemistry,
disordered biology, and resultant bone health compromise.
Thus far, however, assessment and maintenance of nutri-
tional adequacy in relation to the spectrum of essential com-
pounds required for proper bone function has been limited,
as micronutrient strategies have focused almost exclusively
on calcium and vitamin D supplementation [4]. Recent
guidelines have not yet incorporated the fact that some
patients with osteoporosis may be malnourished in relation
to other essential bone nutrients.
Recent research suggests that remediation of nutritional
insuﬃciency and repletion of various biochemicals integral
to healthy bone physiology may ameliorate bone health sta-
tus[16, 17]. This retrospective cohort study, approved by the
Health Ethics Research Board at the University of Alberta,
assesses the value of the use of a combination of micronutri-
ents on BMD status.
2.Methods
A review of the medical and scientiﬁc literature was under-
taken to identify micronutrient elements associated with
bone health status [16] by assessing available medical and
scientiﬁc literature from MEDLINE/PubMed, as well as by
reviewing numerous books, nutrition journals, and health
periodicals, conference proceedings, and government publi-
cations. References cited in identiﬁed publications were also
examined for additional relevant writings. The evidencebase
to support the role of speciﬁc essential micronutrients in
bone statusranges from scant to very ﬁrm, depending onthe
compound [18]. Multiple studies have demonstrated that
micronutrients (and drugs derived from nutrients) beyond
just calcium and vitamin D have an impact on bone health.
Vitamin K2 [19,20],strontium[16,21–25],magnesium[26],
and DHA [27–30] have all been implicated in improving
the status of bones, but to our knowledge, none of these
individual micronutrients have been assessed when given in
combination.
The ﬁrst author practices environmental medicine,
where many referredpatientspresentwithlong-termchronic
disease. With the view that comprehensive fracture risk
assessment should be a routine part of patient care, and the
observation that patients with chronic disease have higher
rates of bone compromise and frequently do not receive
therapy to prevent fractures [31–33], bone health determi-
nation was established as a component of the overall clinical
assessment in chronically ill patients. Starting in 2006,
patientsfoundtohavesuboptimalBMDswere providedwith
options for management, including micronutrient therapy.
As well as discussion related to lifestyle and standard-of-care
pharmaceutical interventions, the potential consequences of
not intervening, and the scientiﬁc literature on the published
eﬃcacy of micronutrient interventions were presented to
patients along with information on recommended clinical
practice guidelines for compromised bone health.
Some patients adamantly refused to use pharmaceutical
therapies while others reported they had previously discon-
tinued such therapy because of continued loss of BMD. A
portion of these individuals indicated interest in supplemen-
tal nutrients linked in the scientiﬁc literature to improved
bone health status. As patients presenting to environmental
health specialists often have chemical sensitivities [34], the
reluctance expressed to using pharmaceuticals was some-
times related to a sensitivity to medications or excipients
commonly used within dispensed drugs.
Patients wishing to explore micronutrient use were given
medical literature detailing the beneﬁts purported in various
studies. Eager to ameliorate their bone health status if possi-
ble,someindividualschosetousemicronutrientsratherthan
using pharmacologic therapieso rn o tu s i n ga n yi n t e r v e n t i o n
at all. After 12 months of consecutive micronutrient therapy,
repeat BMDs were performed to assess for evidence of
change. A retrospective review of the outcomes was under-
taken to gather data for analysis.
2.1. Demographics and Inclusion Criteria. The population of
patients for the study came from an environmental medicine
clinic in Edmonton, Alberta, Canada. Out of 219 patients
assessed, 16 were still in the process of taking supplements
(data not yet complete) and 126 were excluded. Exclusion
criteria included patients with recognized bone compro-
misingmedicalconditionsorthoseonmedicationsknownto
potentially aﬀect bone health. (e.g., 1 with anorexia nervosa
and 1 on chemotherapy) as well as patients who had repeat
BMD measurements inadvertently performed on diﬀerent
machines from the original (5 patients)—making com-
parison inaccurate. In addition, 37 patients were excludedJournal of Environmental and Public Health 3
because they did not comply with therapy (the micronu-
trients were taken inconsistently—self-reported at less than
half the time), 6 patients commencing the protocol changed
their mind about taking the nutrients (for ﬁnancial reasons),
and 71 patients did not return at the end of the time period
for follow-up BMD assessment or decided they did not
want a repeat BMD and therefore had incomplete data. Two
patients died during the course of the study, unrelated to
the intervention (1 from ALS and the other from a motor
vehicle accident). The ﬁnal sample of 77 patients taking
the micronutrient combination most or all of the time was
included with complete data for analysis. Table 2 shows the
demographics for the study group.
2.2. Protocol and Rationale. Each patient in the analysis who
chose to use the micronutrient intervention followed a sug-
gested daily protocol of supplemental nutrient consumption
and exercise as described in Table 1. It was hypothesized that
perhaps bone compromise might be related to nutritional
insuﬃciency in some patients and that remediation of
nutritional biochemistry may be of assistance in restoring
bone health. Also, both DHA and vitamin D are involved in
genetic regulation of many genes and restoration of optimal
levels has been associated with improved bone strength [35–
38]. Given the debate about the eﬃcacy of calcium supple-
mentation for reducing fractures [39, 40] and the potential
risks associated with high-dose supplementation including
renal calculiand cardiovascular events[40, 41],patientswere
advised to obtain calcium from dietary sources including
vegetables such as Brussels sprouts or broccoli rather than
calcium supplements. Patients were also instructed to com-
mence and maintain a regimen of dailyimpact exercises such
as jumping jacks or skipping where possible as impact has
beenassociatedwith preventionofbonedensityloss[42,43].
As BMD is a major determinant among several risk fac-
tors for predicting fragility fractures, BMD follow-up mea-
surement was therefore used as an intervention outcome
alongwithfallsurveillance.Themainareasanalyzedforbone
density includedthe lumbar spine, the femoral neck, and the
femoral trochanter. In this study, we evaluated comparative
diﬀerences in the femoral neck, total hip, and total spine in
relation to previous studies. We also investigated change at
the lowest hip and lowest spine sites to determine whether
there was improvement in the areas that were the least dense
and potentially the most vulnerable.
2.3. Statistics. Statistics were calculated with SPSS 18.0
(IBM Corporation, USA). Pre- and postintervention bone
densities were compared using a one-way ANOVA with a P
value threshold of 0.05. Changes were also evaluated using
mean percentage change overone year to compare treatment
eﬀect with the bisphosphonates and strontium ranelate. In
the analyses, z-scores were used in order to avoid any age-
related bias in some other BMD scores.
In addition, a post hoc analysis of the noncompliant
group (N = 37) was carried out to evaluate whether adher-
ence to the combined micronutrient strategy was beneﬁcial.
One-way ANOVA with a P value threshold of 0.05 was again
Table 1: Combination of micronutrients (COMB) Protocol for
Bone Health.
COMB protocol for bone health
(1) Docosahexanoic acid or DHA (from Puriﬁed Fish Oil):
250mg/day
(2) Vitamin D3: 2000IU/day
(3) Vitamin K2 (non-synthetic MK7 form): 100ug/day
(4) Strontium citrate: 680mg/day
(5) Elemental magnesium:25mg/day
(6) Dietary sources of calcium recommended
(7) Daily impact exercising encouraged
Table 2: Distribution of bone density diagnosis in the sample.
Total (77) Females (72) Males (5)
Postmenopausal — 58 (81%) —
Normal BMD 19 (25%) 16 (22%) 3 (60%)
Reduced BMD 4 (5%) 3 (4%) 1 (20%)
Osteopenia 32 (42%) 32 (44%) 0
Osteoporosis 22 (29%) 21 (29%) 1 (20%)
used to determine if this group showed a signiﬁcant diﬀer-
ence over the course of the one year period. Moreover, the
percentage change at each site in this group was compared to
t h ep e r c e n t a g ec h a n g ei nt h ei n t e r v e n t i o ng r o u p .
Nineteen patients (25%) were classiﬁed in the normal
category despite having low bone mass or suboptimal levels
when age-matched to general population standards. Accord-
ing to the interpretation of the reports provided, the “bone
quality in younger individuals diﬀers from that of older peo-
ple”andthus“absolutefractureriskhasnotbeendetermined
in this population.” As such, diminished bone health with
levels considerably lower than the mean are still placed in
a “normal” diagnostic category. BMD testing was done on
various younger patients as many of these individuals pre-
sented with chronic illness and had evidence of irregularities
onbiochemicalnutritionalstatustesting,orhadotherfactors
that might predispose them to bone health compromise.
3.Results
The population included predominantly women (94%) who
were mostly postmenopausal (81%). Of these patients, 29
(38%) reported lack of success with previous use of bisphos-
phonates and 48 (62%) declined standard drug therapy. The
distributionofbonedensitiesin thesample issummarized in
Table 2.
After treatment, there was a signiﬁcant improvement in
bone density (z-scores) in the femoral neck, total spine as
well as lowest hip and spine scores in the overall group
(Table 3). Improvement was observed in the total hip scores,
but this change was not signiﬁcant.
Overall percentage change after one year is presented in
Figure 1 and comparisons with published results for selected4 Journal of Environmental and Public Health
Table 3: Pre and Posttreatment bone density.
Pretreatment result (Mean ± SD) Posttreatment result (Mean ± SD) P value
Femoral neck (z-score) −0.51 ±0.74 −0.24 ± 0.81 0.03∗
Total hip (z-score) −0.27 ±0.82 −0.06 ± 0.84 0.12
Lowest hip site (z-score) −0.61 ±0.71 −0.27 ± 0.81 0.006∗
L1–L4 spine (z-score) −0.85 ±0.98 −0.39 ± 1.07 0.006∗
Lowest spine site (z-score) −1.40 ±0.95 −0.67 ± 1.07 <0.001∗
∗Signiﬁcant value.
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Figure 1:M e anp e r c e ntc hangeinb oned e nsityfr omb ase lineinthe
intervention group.
pharmaceutical interventions are presented in Table 4.T h e
percent changes in the entire group as shown in Table 4 were
the same when the whole group (males and females, all ages)
was analyzed as when only postmenopausal females were
analyzed. Isolating only the postmenopausal females with
osteopenia and osteoporosis also revealed the same percent-
age changes with the exception of the lowest hip site improv-
ing 5% with this subgroup rather than 4% for the overall
group.In the ﬁve males, there was an even greaterpercentage
change: 10% in the femoral neck, 8% in the total hip, 10%
in the lowest hip site, 10% in the total spine, and 16% in the
lowest spine site. Table 4 compares the results in the current
sample of patients using combination of micronutrients to
strontium ranelate alone [21],aswell astopublishedbispho-
sphonate trials of Alendronate [44]a n dR i s e d r o n a t e[ 45].
The BMD change in one year was more pronounced
in the hip (femoral neck and lowest hip site) among those
who reported lack of success with previous bisphosphonate
therapy (Table 5) and more pronounced in the lowest spine
site among those who had chosen to decline primary
bisphosphonatetherapy. Overthe courseof thestudy period,
there were no fractures from ground level falls in any of
theparticipants. Finally, Figure 2summarizes theproportion
of patients who experienced a BMD change of greater than
3% within the ﬁrst year of following the COMB protocol,
suggesting rapid onset of BMD improvement for many par-
ticipants.
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Figure 2: Proportion of patients showing >3% change in the vari-
ous sites within the ﬁrst year.
Compliance issues have become evident in this study.
Many patients did not complete the 12 month course consis-
tently, but took the intervention sporadically. In this group
of patients (N = 37), a post hoc analysis was carried out
to determine whether sporadic supplementation would be
of beneﬁt. There was no signiﬁcant diﬀerence in z-scores at
any of the sites after one year (P>0.05). At one year, the
percentage change in the femoral neck was −3%, the total
hipwas −1%,thetotalspinewas−2%,thelowesthipsitewas
−2%, and the lowest spine site was −1%. Figure 3 shows the
percentage change after one year in the noncompliant group
(compared to Figure 1 in the compliant group).
4.Discussion
Diminished BMD is an important indicatorof compromised
bone health and has been established as a determinant
associated with fragility fractures. Integrative approaches for
preventing fragility fractures will be essential in addressing
the health concerns in our aging baby boomer population.
In selected patients with diminished bone health, combined
micronutrient therapy may be a promising alternative to
pharmaceutical strategies in order to prevent bone compro-
mise as well as to maintain or to improve BMD.In this study,
we observe that an expanded micronutrient combination
alone can improve BMD in many patients who failed to
achieve success with bisphosphonate medications as well
as those who declined to start bisphosphonate therapy for
reasons of choice or chemical sensitivity.Journal of Environmental and Public Health 5
Table 4: One year of therapy with the COMB protocol compared to strontium ranelate and bisphosphonatemedications.
Percent change
COMB protocol:
one year whole group
(postmenopausal females)
Comparison to Strontium
Ranelate at one year [21]
Comparisonto Alendronate
at one year [44]
Comparison to Risedronate
at one year [45]
F e m o r a l n e c k 4 % 2 %2 %2 %
Total hip 3% 3-4% 2% Not calculated
Lowest hip site 4% Not calculated Not calculated Not calculated
Total spine 6% 5-6% 4% 4%
Lowest spine site 8% Not calculated Not calculated Not calculated
Table 5: Comparison of outcomes between patients who com-
menced the COMB protocol for declined drug therapy and those
who previously showed no improvement on bisphosphonates.
Percent change
Patients who declined
therapy with
bisphosphonate
(N = 48)
Patients who reported
failure with previous
bisphosphonate therapy
(N = 29)
Femoral neck 3% 5%
Total hip 3% 3%
Lowest hip site 4% 5%
Total spine 6% 6%
Lowestspine site 9% 8%
Baseline
Total hip
Femoral neck
Total spine
1 year
−3.5
−3
−2.5
−2
−1.5
−1
−0.5
0
Figure 3: Mean percent change in bone density from baseline in
noncompliantgroup (N = 37).
4.1. Limitations, Confounder, and Strengths. Limitations of
this study include the small sample size and the lack of a
blinded placebo-controlled group. Furthermore, given the
multiple intervention nature of the combination micronu-
trient regimen, it is diﬃcult to pinpoint which nutrients or
nutrientgroupswere ultimatelyresponsiblefortheimproved
BMD in each case. As well, the one-year followup limits the
ability to determine the long-term eﬀects of this regimen
on BMD measurements and sustained prevention of fragility
fractures.
There is also marked selection bias in this study group
which might potentially lead to an underestimate of the full
potential of these interventions in the general population.
Someofthesepatients,forexample,haveunsuccessfullytried
pharmacologic therapies for many years and thus represent
a skewed portion of the population. Furthermore, many of
these patients have multisystem health problems that may
inhibit normal physical activity or may be associated with
other pathophysiologic mechanisms impairing proper bone
physiology.
Each micronutrient in the regimen has prior published
data to suggest eﬀectiveness in improving bone health, but
this is the ﬁrst study to our knowledge that examines these
micronutrients in combination. While it is impossible to
determinewhichcomponentorcomponentsofthemicronu-
trient combination were able to achieve the beneﬁt realized,
the issue of isolating the individual eﬀective component(s)
of the COMB protocol is more of a theoretical than practical
concern. Biochemicals in their natural physiological state as
produced in foods or gut microbiota do not work in isola-
tion.Combinationsofnutrientsareknowntoberequiredfor
normal biochemical function. For example, both vitamin D
and magnesium are required for proper calcium deposition
and bone development [26]. In addition, emerging evidence
suggests that other nutrients including some phytochemicals
may contribute to the constellation of factors involved in
healthy bone biochemistry [46]. Using single supplemental
biochemicals in isolation may not be successful, whereas
using them in combination may be eﬃcacious.
The contention that a combination intervention is less
credible, and that a traditional prospective clinical trial iso-
lating individual variables to determine independent eﬃcacy
compared to controls is required to demonstrate beneﬁt
and to recommend micronutrient therapies, is debatable.
With the emergence of molecular medicine and the Human
Genome Project (HGP) recently identifying each person as
b i o c h e m i c a l l yu n i q u e ,i tm a yn o tb ev a l i dt os a yt h a ta n y
single therapy used broadly will work in a similar fashion for
individual patients as genomic variability already introduces
multivariables. The HGP has demonstrated that genomic
solitary nucleotide polymorphisms (SNPs) regulate genomic
function and aﬀect the function of enzymes they code for,
thusraising thequestionofwhat constitutesapropercontrol
group [47, 48]. Most clinical trials to date have controls
based on race, age, and sex, but genomic variables with SNP
variability may be just as signiﬁcant as race, sex, and age as
determinants of physiological outcome. Emerging evidence6 Journal of Environmental and Public Health
shows that SNP variability is enormous within race and sex
groups and many published clinical trials, including osteo-
porosis research, which omit relevant genomic information
may not have proper controls and are, at best, anecdotal.
The rapidly emerging ﬁeld of genomics is increasingly
supplanting knowledge gleaned from broad-based clinical
trials in many branches ofmedicine [49–51] and has ushered
in the expansion of pharmacogenomics and nutrigenomics
to speciﬁcally assess and treat individuals according to
their unique biochemistry [52]. Furthermore, the Human
Microbiome Project has recently uncovered the individual
nature of the gut microﬂora [53], creating further evidence
of individual biochemistry, a unique gut microbiome, and
resultant unique physiology. Broad-based research without
genomic controls, identifying a single pharmacologic agent
as a widespread therapy for osteoporosis or any other condi-
tion may be judged to have inadequate experimental design
and thus scientiﬁcally unreliable. Accordingly, reproducible
clinical interventions which yield positive clinical outcomes,
as in this study, deﬁnitely have limitations but may have at
least comparable merit to traditional trials when considering
beneﬁt.
4.2. Strontium Citrate and Strontium Ranelate. It has repeat-
edly been documented in the literature that pharmacologic
therapy with strontium ranelate is associated with an eleva-
tion in BMD as well as reduction in fragility fractures [16,
21–25]. Since strontium is a metal in the same group of peri-
odic elements as calcium, it has been recognized that stron-
tium in high concentrations may displace and replace cal-
cium in bone by heteroionic exchange [54], a phenomenon
which has elicited disparaging regard for strontium therapy
among some bone specialists. Rather than an increased
BMD, however, this physiochemical process in the presence
of excessive strontium ultimately results in decreased bone
calcium content [55], dissolution of mineralized bone [56],
disruption of bone architecture [57], and lower BMD [58].
This phenomenon only appears to be the consequence
of disproportionately high doses of strontium intake, not
regular supplemental levels at low dose.
At low supplemental doses of strontium, in fact, there is
evidence of an increase in both the bone formation rate and
the trabecular bone density related to a strontium-induced
stimulation of osteoblastic activity [58]. Furthermore, at low
doses, strontium is not associated with any mineralization
defectoranyincrease inthenumberofactivebone-resorbing
cells [59, 60]. In addition, it has recently been found that the
mechanism of strontium beneﬁt may also involve a calcium
preservation eﬀect as the rate of calcium release was almost
halved after strontium treatment was assessed in recent
research on teeth [61]. Finally, strontium supplementation,
unlike use of calcium supplementation, shows ability to
recalcify osteopenic areas in pathological bone conditions
characterized by accelerated bone loss and extensive dem-
ineralization [58, 62].
Strontium is increasingly being recognized as a trace
mineralwhichmaybeessentialtothenormalbiologyofbone
and teeth and it is yet undetermined if strontium deﬁciency,
like iodine deﬁciency, results in physiological malfunction
[63]. It has been recently reported that commercial foods
grown on ﬁelds using synthetic fertilizers, pesticides, and
herbicides have appreciably lower levels of strontium than
organic food counterparts [64]. Thus the restoration of ade-
quate strontium levels to individuals may simply represent
the normal homeostatic requirement for strontium, and
normal healthy bone may require some level of strontium
to prevent calcium loss [61]. Most importantly, treatment
to elevate strontium levels has repeatedly been shown to
demonstrate safe and remarkable eﬃcacy at diminishing
fractures in hip, vertebral as well as peripheral sites [21–25].
Studiestodatehavepredominantlyfocusedonstrontium
ranelate rather than the readily available strontium citrate
supplement as used in this study. The results of this study,
however, demonstrate that the micronutrient combination
including strontium citrate is at least as eﬀective in BMD
change as strontium ranelate with suggestion of preferred
eﬃcacyoftheformertherapyatimprovingfemoralneckout-
comes.Furthermore, theranelicacidsalt isapurelysynthetic
molecular compound, while citrate is naturally occurring.
It appears to be the strontium portion of the molecules
which exerts most or all of the positive eﬀect on bone.
When consuming the strontium ranelate, for example, the
compound splits into two strontium ions and one molecule
of ranelic acid, with each absorbed separately. There is little
evidence that the ranelic acid portion of the strontium
ranelate compound contributes to the eﬀect of strontium on
skeletal tissue, and of the small amount of ranelic acid that is
absorbed into the body, almost all is excreted within a week
without everbeing metabolized. All forms of strontium have
bioavailabilities in the 25–30% range, but gastric tolerance
appears to be better with the ranelate and citrate forms.
With the mounting concern about the safety proﬁle of
some standard medical interventions for bone compromise,
strontium is very well tolerated and has shown remarkably
l i t t l ei nt h ew a yo fs i d ee ﬀects or long-term adverse sequelae.
An increased risk of thrombosis has been noted with
strontiumranelate,aneﬀectnotreported(toourknowledge)
with strontium citrate [16].
4.3. Mechanism of Action of Micronutrients. Unlike pharma-
cologic interventions, it is hypothesized that micronutrient
strategies do not work by altering physiological parameters
such as osteoclast function, but rather function by remedi-
ating underlying nutritional deﬁciencies which then permit
restoration of inherent physiological processes. It is increas-
ingly documented that nutritional deﬁciency continues to be
an unrecognized and undertreated problem in clinical prac-
tice [65, 66]. Compromised nutritional status has recently
been correlated with diminished quality of life and increased
morbidity and mortality [67, 68]. It is well established that
adequate weight and BMI, oft assumed to indicators of
nutritional suﬃciency, underestimate nutritional status and
risk [69]. Investigation and management of malnutrition,
often found in those with chronic disease, should become
standard practice in clinical medicine [65, 70].
4.4. Relative Cost of COMB Protocol. An important factor to
consider in evaluating this combination of micronutrientsJournal of Environmental and Public Health 7
forbonehealth isthecosttopatients, giventhatsupplements
are generally not covered by public formularies while many
pharmaceuticals used for osteoporosis receive coverage. The
current COMB protocol was evaluated at $2.26 (CDN)
per day, amounting to $67.80 per month or $824.90 per
year. Bisphosphonates, on the other hand, range from $0.90
(least expensive generic preparation) per day to $12.96
(brand name) per day for Risedronate and $1.10 per day
(least expensive generic) to $5.58 per day (brand name) for
Alendronate (according to Blue Cross coverage for Alberta,
Canada). A small percentage of the group discontinued
the micronutrient intervention because they felt it was too
e x p e n s i v et op u r c h a s et h en u t r i e n t s ,w h i c hw e r en o tc o v e r e d
by their drug plans. Given the potential cost saving in
maximizing bone health, it would be prudent for govern-
ment formulary administrators to consider funding such a
protocol in appropriate patients.
4.5. Public Health Considerations. From a public health per-
spective, a number of fundamental questions need to be ad-
dressed.
(i) Why is there an epidemic of impaired bone health?
(ii) Why is the incidence and prevalence of osteoporosis
increasing?
(iii) Why is there disparity in the geographic distribution
of osteoporosis?
(iv) Why does osteoporosis frequently occur in individu-
als with no family history of bone compromise?
Genetics have not changed in the last three decades but
lifestyle and environmental factors inﬂuencing bone health
have. While use of pharmaceuticals may diminish risk of
fracture in individual cases, they do not address the eti-
ology or underlying cause of bone compromise; osteo-
porosis is not a bisphosphonate-deﬁciency disease. Accord-
ingly, any prevention strategy must investigate and address
lifestyle, nutritional and environmental determinants that
have contributed to the rise in bone health compromise. The
marked improvement in BMD with simple micronutrients
in this study raises the question as to whether nutrient deﬁ-
ciency is a widespread phenomenon and a major determi-
nant of this public health problem. Comprehensive research
on nutritional status of patients with osteoporosis needs
to be undertaken to determine if nutritional deﬁciency is
af a c t o r .
It has been well documentedthat vitamin Dinsuﬃciency
is a widespread reality and a determinant of myriad health
problems includingbone compromise [71]. Achallenge with
the consideration of nutritional status assessment, however,
is that levelsof some essential nutrients for bone metabolism
such as strontium and vitamin K2 are not yet available in
most laboratories. Accordingly,clinical suspicion, laboratory
testingwherepossible,andrepletionofnutrientsrequiredfor
normal bone physiology may represent the best that can be
done with regards to nutritional management at the current
time.
5.ConcludingThoughts
Osteoporosis has become a serious personal health issue for
countless individuals as well as a disturbing public health
problem for many countries as it now aﬀects up to 1 in 2
women and 1in 5men overthe ageof 50 in some population
groups [5]. Fragility fractures associated with impaired bone
health account for widespread morbidity and, in the case
of hip and vertebral fractures, undue rates of mortality
[4]. Public expenditures associated with the management of
osteoporotic fractures and their complications are staggering
[3]. Left untreated, impaired bone health often has debilitat-
ing sequelae for individuals and profound implications for
public health care.
The current practice standard for making a diagnosis of
impaired bone health involves bone density measurement in
conjunctionwithdeterminationofclinicalriskfactors.Based
on this combined assessment, clinical decisions to intervene
with treatment are routinely made. The objective of any
treatment toimprove bonehealth, medicationsorotherwise,
is to reduce the risk of fragility fractures in the future. It
has been repeatedly established that those individuals with
deﬁcient bone mineral density, as measured by densitometry
testing, are at increased risk for fragility fractures [72, 73].
It has been found that timely and eﬀective management of
compromised bone health, as diagnosed in part by subopti-
mal BMD measurements, can reduce fracture risk [6]. Mea-
sures which are successful in improving BMD measurements
have been found to diminish the risk of fragility fractures
[21, 74].
Interventions to improve BMD usually include the use
of bisphosphonate or other pharmacologic options includ-
ing teriparatide, strontium ranelate, raloxifene, hormone
therapy, or calcitonin. However, there are some individuals
who do not tolerate these medications, some that have not
experiencedimpr ovedBMDwiththesetr eatments,andsome
who decline to take these therapies because of reluctance to
use medication in general, or because of increasing media
attention to potential adverse eﬀects associated with some
osteoporosis drugs. Accordingly, some authors have recom-
mended that nonpharmacologic strategies to improve or
maintain bone health be included in discussion of options
for bone preservation and therapy [6].
In this study, we introduce the use of a combination of
micronutrients, each of which has previously been shown
individually in the medical and scientiﬁc literature to beneﬁt
BMD outcomes. To assess the value of any therapy for com-
promised bone strength, one should ask if it fulﬁlls the fol-
lowing criteria:
(i) protection from fragility fractures at multiple skeletal
sites;
(ii) rapid onset of action in order to provide beneﬁt as
soon as possible;
(iii) minimal side eﬀects for maximum tolerability;
(iv) long-term safety;
(v) patient acceptability.8 Journal of Environmental and Public Health
It appears that the COMB strategy may fulﬁll many of
thesecriteria.Theprotectionfromfragilityfractureswassug-
gested by the occurrence of no fractures in the group taking
the intervention as well as a notable increase in BMD at
femur, hip, and spine sites on the BMD testing. A major
proportion of the patients had an increase in BMD of more
than 3% within the ﬁrst year of therapy alone. There were no
reported side eﬀectswith theuse ofthistherapyamong those
takingtheinterventionfortheyearandtheliteraturesuggests
long-term safety with each of these agents—this might con-
tribute to greater compliance with the subgroup of patients
who are reluctant to use pharmacologic therapies. For those
who completed the course of therapy, the acceptability was
high.
In response to these ﬁndings, two questions arise:
(i) How does nutritional supplementation work for dis-
ordered bone strength?
(ii) Does micronutrient therapy have any role in main-
stream medical practice?
A scientiﬁc approach to illness necessitates exploring
the source etiology of health problems when possible and
addressing causative determinants, including biochemical
deﬁciencies [75]. From the results of this study it is hypoth-
esized that osteoporosis in some cases may be related to
nutritional deﬁciency of selected nutrients. Nutrient bio-
chemicals are the fundamental building blocksof the human
body, including the skeletal system; deﬁciency of required
nutrients resultsindisordered biologyand disease. Repletion
of such nutrients may spontaneously correct and perhaps
cure bone compromise in both young and mature patients.
Just as restoring gestational folic acid to prevent open neural
tube defects or supplementing with iron to ameliorate iron-
deﬁciency anemia are recognized as credible and indicated
nutritional interventions, remediation of essential biochem-
icals to restore and maintain bone strength is both evidence-
based and science-based medicine. Further research of
micronutrient strategies with longerfollowup will be needed
to explore the eﬀectiveness of this approach to disorders of
bone health, but these preliminary results are encouraging
indeed.
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